Genetically modified organoids expressing high levels of KRT17 (ptGPC crKRT17 and FL KRT17 lines), which also displayed high levels of platinum resistance, provided a model to explore the response of ovarian cancer to targeted agents, as they reflect the potentially relevant clinical scenario of heavily pre-treated, platinum-resistant, and highly KRT17-expressing tumors. This evidence concerns the gene KRT17 and ovarian cancer.